Aeglea BioTherapeutics, Inc. – NASDAQ:AGLE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Aeglea BioTherapeutics stock price monthly change
-4.83%
month
Aeglea BioTherapeutics stock price quarterly change
+1921.98%
quarter
Aeglea BioTherapeutics stock price yearly change
+812.40%
year
Aeglea BioTherapeutics key metrics
Market Cap | 48.62M |
Enterprise value | N/A |
P/E | -0.27 |
EV/Sales | -3.66 |
EV/EBITDA | 0.10 |
Price/Sales | 9.31 |
Price/Book | 0.43 |
PEG ratio | -0.27 |
EPS | -71.22 |
Revenue | N/A |
EBITDA | 104.55M |
Income | -294.43M |
Revenue Q/Q | -100% |
Revenue Y/Y | -81.84% |
Profit margin | -3598.75% |
Oper. margin | -3640.23% |
Gross margin | 0% |
EBIT margin | -3640.23% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAeglea BioTherapeutics stock price history
Aeglea BioTherapeutics stock forecast
Aeglea BioTherapeutics financial statements
| Dec 2022 | 168K | -18.82M | -11203.57% |
|---|---|---|---|
| Mar 2023 | 198K | -18.42M | -9304.04% |
| Jun 2023 | 688K | -217.08M | -31552.47% |
| Sep 2023 | 0 | -40.10M |
| 2025 | 9.31M | -63.21M | -678.52% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 71144000 | 20.83M | 29.29% |
|---|---|---|---|
| Mar 2023 | 52453000 | 18.80M | 35.84% |
| Jun 2023 | 243529000 | 450.89M | 185.15% |
| Sep 2023 | 207265000 | 452.66M | 218.4% |
| Dec 2022 | -18.14M | 14M | -8K |
|---|---|---|---|
| Mar 2023 | -17.63M | 17.75M | 10K |
| Jun 2023 | -16.64M | 6.76M | 209.99M |
| Sep 2023 | -34.59M | -97.63M | -12.53M |
Aeglea BioTherapeutics alternative data
| Aug 2023 | 61 |
|---|---|
| Sep 2023 | 14 |
| Oct 2023 | 14 |
| Nov 2023 | 14 |
| Dec 2023 | 69 |
| Jan 2024 | 69 |
| Feb 2024 | 69 |
| Apr 2024 | 69 |
| May 2024 | 69 |
| Jun 2024 | 69 |
| Jul 2024 | 69 |
Aeglea BioTherapeutics other data
9.45%
-35.85%
of AGLE is owned by hedge funds
21
-27
7.96M
-34.70M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 253634 | 0 |
| Mar 2022 | 299745 | 0 |
| Jun 2022 | 28200 | 0 |
| Aug 2022 | 90000 | 0 |
| Patent |
|---|
Application Filling date: 28 Aug 2020 Issue date: 24 Jun 2021 |
Application Filling date: 3 Aug 2020 Issue date: 19 Nov 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2018 8 Mar 2019 | Q4 2018 Earnings Call Transcript |
| Q4 2016 24 Mar 2017 | Q4 2016 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP (1962) Pres, Chief Executive Officer & Director | $819,750 |
| Dr. Leslie S. Sloan Ph.D. (1971) Chief Operating Officer | $538,350 |
-
When is Aeglea BioTherapeutics's next earnings date?
Unfortunately, Aeglea BioTherapeutics's (AGLE) next earnings date is currently unknown.
-
Does Aeglea BioTherapeutics pay dividends?
No, Aeglea BioTherapeutics does not pay dividends.
-
How much money does Aeglea BioTherapeutics make?
Aeglea BioTherapeutics has a market capitalization of 48.62M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 87.57% to 2.33M US dollars.
-
What is Aeglea BioTherapeutics's stock symbol?
Aeglea BioTherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AGLE".
-
What is Aeglea BioTherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aeglea BioTherapeutics?
Shares of Aeglea BioTherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aeglea BioTherapeutics's key executives?
Aeglea BioTherapeutics's management team includes the following people:
- Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP Pres, Chief Executive Officer & Director(age: 63, pay: $819,750)
- Dr. Leslie S. Sloan Ph.D. Chief Operating Officer(age: 54, pay: $538,350)
-
How many employees does Aeglea BioTherapeutics have?
As Jul 2024, Aeglea BioTherapeutics employs 69 workers.
-
When Aeglea BioTherapeutics went public?
Aeglea BioTherapeutics, Inc. is publicly traded company for more then 9 years since IPO on 7 Apr 2016.
-
What is Aeglea BioTherapeutics's official website?
The official website for Aeglea BioTherapeutics is aeglea.com.
-
Where are Aeglea BioTherapeutics's headquarters?
Aeglea BioTherapeutics is headquartered at 805 Las Cimas Parkway, Austin, TX.
-
How can i contact Aeglea BioTherapeutics?
Aeglea BioTherapeutics's mailing address is 805 Las Cimas Parkway, Austin, TX and company can be reached via phone at +51 29422935.
Aeglea BioTherapeutics company profile:
Aeglea BioTherapeutics, Inc.
aeglea.comExchange:
NASDAQ
Full time employees:
69
Industry:
Biotechnology
Sector:
Healthcare
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
805 Las Cimas Parkway
Austin, TX 78746
Austin, TX 78746
CIK: 0001636282
ISIN: US00773J2024
CUSIP: 00773J103
